BioSpace News Archive

Chordia Therapeutics Inc. announced that it has presented the interim results from the Phase 1 clinical trial of CTX-712, a selective pan-CDC-like kinase inhibitor discovered by Chordia, at the 2022 Annual Meeting of the American Society of Clinical Oncology, which was held from June 3 to June 7.

ECP Pharma has received a favorable, positive written response from the FDA regarding its Pre-IND submission of novel drugs for targeted indications with no clinically proven treatment options using underutilized APIs.

Lantronix Inc. (NASDAQ: LTRX), a global provider of secure turnkey solutions for the Industrial Internet of Things (IoT) and the Intelligent IT market, today announced that its Open-Q™ Micro SOM (μSOM), Development Kit and Engineering Services were utilized by EchoNous in the development of Kosmos, the first AI-assisted handheld ultrasound device.

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, will participate in fireside chats at two upcoming investor conferences.

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference in Rancho Palos Verdes, California.

Wilmington, Delaware, United States: Uterine cancer is the most common cancer that occurs in the female reproductive system.

OSE Immunotherapeutics SA and its clinical partners GERCOR, ARCAGY-GINECO and the FoRT Foundation, presented four posters featuring neoepitope specific immunotherapy Tedopi® in various cancer indications at the American Society of Clinical Oncology Annual Meeting held June 4 – 7.

Sensorion announces, that the initiation of a Proof of Concept clinical trial of SENS-401 in patients scheduled for cochlear implantation has been approved by regulatory authorities in France.

MRM Health announces the publication of preclinical research relating to its ongoing program in non-alcoholic fatty liver disease, with a 9-strain live bacterial consortium resulting from its proprietary and unique CORAL® platform technology.

Biodesix, Inc. announced that WPS Government Health Administrators, the Medicare Administrative Contractor with jurisdiction for Biodesix’s De Soto, Kansas laboratory, has provided coverage for the Nodify CDT® lung nodule test.